Angel Nutritech unveils probiotic allergy prevention drops for infants in China
07 May 2021 --- Angel Nutritech, a business unit of Angel Yeast, has launched probiotic drops and powder as an early intervention against infant allergies and for babies under 1 already suffering from allergies.
Probiotic Complex Drops are formulated with two strains from Chr. Hansen, which work in synergy: Lactobacillus rhamnosus (LGG) and Bifidobacterium animalis (BB-12).
The product is positioned for the Chinese market where “nearly half of all babies suffer from allergic diseases,” notes Angel Nutritech.
Symptoms include skin flush and pruritus in minor cases, while some may need to take hormone drugs for treatment in severe cases, which could affect their health and growth.
Differentiating oneself on the market
The strains are imported with original packing from Chr. Hansen in Denmark and are industrially recognized.
The two strains working in tandem is a plus, notes Angel Nutritech, as other probiotics on the market “seldomly have complex strains.”
Moreover, Angel Yeast affirms that the Probiotic Complex Drops with LGG and BB-12 delivers nearly 2 billion strains in a single day, compared to the industry standard of 1 billion.
LGG and BB-12 Probiotic Complex Drops are positioned for babies younger than 1 who are at risk of or have allergies.Tiny sneezes
According to Angel Yeast, clinical data indicates the prevalence rate of babies suffering from atopic dermatitis in China is up to 30.48 percent. This finding suggests that one-third of babies younger than 1 have allergic eczema symptoms.
Angel Yeast also notes the ratio of the babies who suffered or are suffering from allergic disease symptoms among 0-24 month-old babies is as high as 40.9 percent, according to parent reports.
The repetitiveness and complications of allergic diseases are threatening babies’ health and growth, and imposing significant mental pressure on parents, notes the company.
Studies to back claims
Chr. Hansen’s LGG and BB-12 have been investigated in various human clinical studies to support their efficacy.
Non-specific immunity guided by dendritic cells and macrophages enhances the protective effects of the mucous membrane.
The BB-12 can be found in close to 400 scientific publications, of which more than 130 publications involve the clinical study on human bodies. Many of these demonstrated the strain’s function on stomach and intestine health and immunologic functions.
BB-12 is the only Bifidobacterium strain with the whole genome sequence obtained. LGG has also been well documented, with studies linking the strain to clinical eczema applications.
With the LGG strain, the effects for eczema prevention in high-risk children can be extended up to age 4, notes the company.
Other clinical studies suggest LGG’s impact on respiratory tract infections, colds and diarrhea.
Ready for the market
The strains are approved by the former National Health and Family Planning Commission of the People’s Republic of China to be used for infants and children, and thus safer and more convenient for babies younger than 6 months.
The pure formula of LGG and BB-12 contains no sweetening agent and is free from fragrances or allergens. Both powder and drop forms are available to suit the needs of the infant’s caretakers.
Collaboration across the world
Last November, Angel Yeast signed a letter of intent for cooperation with Chr. Hansen and Novozymes from Denmark for the development of probiotics and enzymes.
Chr. Hansen’s BB-12 strain was recently spotlighted in plant-based yogurt for its health benefits ranging from immunity to oral health.
By Missy Green
